Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | PYGB | P11216 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538422 | 1.00 | AKR1B1 (0.46) | AKR1B1CA1CA2CA9PYGB | |
| SCHEMBL1980707 | 1.00 | AKR1B1 (0.46) | AKR1B1CA1CA2CA9PYGB | |
| SCHEMBL9757541 | 0.89 | AKR1B1 (0.45) | AKR1B1CA1CA2CA9PYGB | |
| SCHEMBL9757745 | 0.84 | AKR1B1 (0.43) | AKR1B1CA1CA2CA9PYGB | |
| SCHEMBL3810831 | 0.83 | CA1 (0.50) | AKR1B1CA1CA2CA9PYGB | |
| SCHEMBL9616492 | 0.83 | CA1 (0.50) | AKR1B1CA1CA2CA9PYGB | |
| SCHEMBL18642492 | 0.83 | CA1 (0.50) | AKR1B1CA1CA2CA9PYGB | |
| SCHEMBL7253811 | 0.83 | CA1 (0.50) | AKR1B1CA1CA2CA9PYGB | |
| SCHEMBL6934741 | 0.83 | CA1 (0.50) | AKR1B1CA1CA2CA9PYGB | |
| SCHEMBL5189446 | 0.83 | AKR1B1 (0.53) | AKR1B1CA1CA2CA9PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| EP-4114963-A1 | METHODS OF CONTROLLING BODYWEIGHT BY MODULATING PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE BETA ACTIVITY | University of Cincinnati (US) | 2023-01-11 | — | — | EP | claimed |
| EP-3687543-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | claimed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | claimed |
| EP-3262048-A1 | ANTIVIRAL COMPOUNDS | Alios Biopharma, Inc. (US) | 2018-01-03 | — | — | EP | claimed |
| WO-2016138158-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2016-09-01 | — | — | WO | claimed |
| EP-3036220-A1 | ANTIVIRAL COMPOUNDS | Alios Biopharma, Inc. (US) | 2016-06-29 | — | — | EP | claimed |
| WO-2015026792-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2015-02-26 | — | — | WO | claimed |
| JP-2012500104-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2320991-A2 | DEVICE AND METHOD FOR DRUG EVALUATION AND LOCAL TREATMENT | Third Rock Ventures (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010022252-A2 | DEVICE AND METHOD FOR DRUG EVALUATION AND LOCAL TREATMENT | THIRD ROCK VENTURES (US) | 2010-02-25 | — | — | WO | claimed |
| EP-1765336-A2 | ANGIOGENESIS INHIBITORS | THE JOHNS-HOPKINS UNIVERSITY (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006004795-A2 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-12 | — | — | WO | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| EP-1363704-A2 | DAPD COMBINATION THERAPY WITH INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITOR | Triangle Pharmaceuticals Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| WO-2002068058-A2 | DAPD COMBINATION THERAPY WITH IMDPH INHIBITORS SUCH AS RIBAVIRIN OR MYCOPHENOLIC ACID | TRIANGLE PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | claimed |
| EP-1154787-A2 | SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES | Institute of Molecular and Cell Biology (SG) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050064-A2 | SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES | INSTITUTE OF MOLECULAR AND CELL BIOLOGY (SG) | 2000-08-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | AKR1B1 2536/4885CA1 4181/4885CA2 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.